Db Fitzpatrick & Co, Inc Amgen Inc Transaction History

Db Fitzpatrick & Co, Inc

$113 Million
Q3 2024

A detailed history of Db Fitzpatrick & Co, Inc transactions in Amgen Inc stock. As of the latest transaction made, Db Fitzpatrick & Co, Inc holds 4,287 shares of AMGN stock, worth $1.2 Million. This represents 1.22% of its overall portfolio holdings.

Number of Shares

4,287

Previous 4,311 0.56%

Holding current value

$1.2 Million

Previous $1.35 Million 2.6%

% of portfolio

1.22%

Previous 1.25%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 16, 2024	SELL	$309.38 - $337.38 $7,425 - $8,097	-24 Reduced 0.56%	4,287 $1.38 Million
Q2 2024 Jul 17, 2024	BUY	$262.75 - $319.31 $671,063 - $815,517	2,554 Added 145.36%	4,311 $1.35 Million
Q1 2024 Apr 19, 2024	SELL	$268.87 - $324.56 $618,669 - $746,812	-2,301 Reduced 56.7%	1,757 $499,000
Q4 2023 Jan 23, 2024	BUY	$255.7 - $288.46 $4,858 - $5,480	19 Added 0.47%	4,058 $1.17 Million
Q3 2023 Nov 01, 2023	BUY	$218.65 - $271.46 $19,459 - $24,159	89 Added 2.25%	4,039 $1.09 Million
Q2 2023 Aug 09, 2023	SELL	$214.27 - $253.37 $38,354 - $45,353	-179 Reduced 4.34%	3,950 $876,000
Q1 2023 Apr 24, 2023	BUY	$225.79 - $275.2 $491,996 - $599,660	2,179 Added 111.74%	4,129 $998,000
Q4 2022 Jan 24, 2023	SELL	$229.03 - $291.01 $157,572 - $200,214	-688 Reduced 26.08%	1,950 $0
Q3 2022 Oct 20, 2022	SELL	$224.46 - $253.15 $59,032 - $66,578	-263 Reduced 9.07%	2,638 $595,000
Q2 2022 Jul 28, 2022	BUY	$230.71 - $256.74 $11,304 - $12,580	49 Added 1.72%	2,901 $706,000
Q1 2022 Apr 22, 2022	SELL	$219.27 - $242.57 $261,589 - $289,386	-1,193 Reduced 29.49%	2,852 $690,000
Q4 2021 Feb 03, 2022	BUY	$198.88 - $227.6 $804,469 - $920,642	4,045 New	4,045 $910,000

Others Institutions Holding AMGN

# of Institutions

3,120

Shares Held

410M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $150B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Db Fitzpatrick & Co, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Db Fitzpatrick & Co, Inc with notifications on news.

Account

Db Fitzpatrick & Co, Inc Amgen Inc Transaction History